huNOG-EXL EA (Early Access): A Myeloid-Supportive HIS Model with a Longer Potential Study Window
Thursday, February 17, 2022 | 11 a.m. ET / 5 p.m. CET
Join us for an informative webinar discussing the advantages of utilizing Taconic Biosciences' huNOG-EXL EA option for research studies.
The huNOG-EXL is a versatile humanized immune system mouse which supports development of both lymphoid and myeloid cells. The new huNOG-EXL EA option allows more flexibility in study design, particularly for certain challenging scenarios.
During this webinar, you’ll gain an understanding of how inter- and intra-donor variability can impact experimental outcomes and how Taconic controls for these in humanized mice production.
The huNOG-EXL EA model can:
- Maximize the possible study window for huNOG-EXL mice
- Provide a sufficient study window for efficacy studies using slow-growing tumors or with longer treatment paradigms
- Allow for the start of experimentation in huNOG-EXL mice prior to emergence of T cells or during the peak B cell period
- Overcome unavoidable logistics and quarantine challenges, which may reduce the study window unacceptablely when using the standard huNOG-EXL offering
Senior Scientist | Taconic BIosciences
Dr. Janell Richardson has 15 years of in vivo pharmacology experience. She received her doctorate in 2012 from Georgetown University in Pharmacology. She continued on to a post-doctoral fellowship and subsequently moved into industry in 2015. In the commercial sector, she led an early target identification in vivo pharmacology team. In 2018, she joined Taconic as a field scientist and now leads Taconic’s R&D efforts.